Ergothioneine
1. Identity: Chemical Names, Structure, and Natural Sources
1.1 Chemical and Botanical Identity
L-Ergothioneine (EGT) is a natural thiourea derivative of histidine that exists in two tautomeric forms: a thiol form and a thione form. More precisely, ergothioneine is a histidine betaine derivative with a thiol group attached to the C2 atom of the imidazole ring. Its molecular formula is C9H15N3O2S. Ergothioneine presents two tautomeric forms: the thione, which is the majoritarian and more stable form, and the thiol. The compound is water-soluble and zwitterionic at physiological pH.
Common synonyms and systematic names include: L-ergothioneine; 2-mercapto-L-histidine betaine; (S)-α-carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethanaminium inner salt; and, in commercial preparations, the branded name Ergoneine®. The water-soluble amino acid L-ergothioneine (2-mercapto-L-histidine betaine) occurs primarily in mushrooms.
1.2 Discovery
Ergothioneine was discovered by Charles Tanret in 1909 and named after the ergot fungus from which it was first purified, with its structure being determined in 1911. As a natural compound, L-ergothioneine was first isolated from rye ergot (Claviceps purpurea) in 1909.
1.3 Natural Sources and Biosynthesis
Ergothioneine is a sulfur-containing histidine derivative synthesized by many bacteria and most fungi, but it also finds its way into human tissue by way of specific absorption from the diet. Ergothioneine is a natural compound produced in Actinobacteria such as Mycobacterium smegmatis and filamentous fungi such as Neurospora crassa. Other species such as Bacillus subtilis, Escherichia coli, Proteus vulgaris, and Streptococcus, as well as fungi belonging to the groups Ascomycetes and Deuteromycetes, cannot make ergothioneine. Animals and plants also cannot make ergothioneine and must obtain it from dietary sources or, in the case of plants, from their environment.
More recently, Pfeiffer and colleagues (2011) demonstrated that several species of cyanobacteria can produce large amounts (up to 800 mg/kg dry mass) of this compound. In samples of cyanobacterial preparations used as dietary supplements for humans — examples include Aphanizomenon flos-aquae and Spirulina platensis — ergothioneine's concentration has been measured to be up to 600 mg/kg dry mass.
The metabolic pathway to produce ergothioneine starts with the methylation of histidine to produce histidine betaine (hercynine). The sulfur atom is then incorporated from cysteine. The biosynthetic genes of ergothioneine have been described in detail for Mycobacterium smegmatis, Neurospora crassa, Schizosaccharomyces pombe (with homologues in Aspergillus, a genus important in food fermentation), and Caldithrix abyssi. Research has revealed that ergothioneine biosynthesis has emerged at least three times by independent molecular evolution.
1.4 Dietary Food Sources
Mushrooms are typically the richest source of ergothioneine in the human diet, with amounts of ergothioneine varying widely depending on strain and growing conditions. Differences in cultivation practices, including cultivation substrates, and soil health and tillage methods, likely explain much of the large variation observed in the ergothioneine contents of both mushrooms and other foods from different places of production.
The highest concentrations of L-ergothioneine are found in mushrooms, particularly Boletus edulis (porcini mushroom, 528.14 mg/kg) and Pleurotus ostreatus (oyster mushroom, 118.91 mg/kg). A survey of ergothioneine content of commonly consumed mushrooms in the United States found levels from about 400 to 2000 mg/kg dry weight. The lowest level was found in the most consumed button mushrooms (Agaricus bisporus), and about 4-fold higher levels were found in specialty mushrooms such as Shiitake (Lentinula edodes), Oyster, and Maitake (Grifola frondosa).
Ergothioneine levels across mushroom species varied widely (0.15–7.27 mg/g dry weight) and were highly correlated with those of glutathione. Both antioxidants were more concentrated in the pileus (cap) than the stipe (stem) tissues.
Ergothioneine is also found in relatively high concentration in liver (chicken, 10.78 mg/kg), black turtle beans (13.49 mg/kg), red kidney beans (4.52 mg/kg), and oat bran (4.41 mg/kg). Foods found to contain ergothioneine include liver, kidney, black beans, kidney bean, and oat bran, with the highest levels in bolete and oyster mushrooms, especially in Pleurotus citrinopileatus. Levels can be variable, even within species, and some tissues can contain much more than others.
Since ergothioneine is produced primarily by fungi, mushrooms are the leading dietary source, but ergothioneine is found in relatively low amounts throughout the food chain as a result of soil-borne fungi or bacteria passing it on to plants through their roots. Some conventional agricultural practices that negatively impact soil fungi, such as excessive soil disturbance (ploughing), can significantly reduce ergothioneine content of food crops when compared to regenerative practices such as eliminating tillage (no-till).
1.5 Tissue Distribution in the Human Body
In the human body, the largest amounts of ergothioneine are found in erythrocytes, eye lens, semen, and skin. Ergothioneine neutralizes reactive oxygen species (ROS), limits lipid peroxidation, and maintains redox homeostasis, particularly in tissues prone to oxidative injury such as the liver, brain, and kidneys.
1.6 Commercial Forms and Preparations
Ergothioneine is widely utilized in food processing, cosmetics, pharmaceuticals, and nutritional supplements. Current bioproduction methods for ergothioneine primarily depend on fermenting edible mushrooms. However, with the advancement in synthetic biology, an increasing number of genetically engineered microbial hosts have been developed for ergothioneine production, including Escherichia coli, Saccharomyces cerevisiae, and Corynebacterium glutamicum. Blue California, the first to produce L-ergothioneine via fermentation, launched its ErgoActive ingredient in 2015 as an alternative to chemical synthesis and mushroom extraction, and received FDA Generally Recognized as Safe (GRAS) status in 2019. In supplemental commerce, ergothioneine is sold principally as oral capsules or tablets. It has been widely used as a dietary supplement and cosmetic additive.
2. Traditional and Historical Use
Ergothioneine as a purified, isolated compound has no pre-modern ethnobotanical or traditional medicinal history, as its identification is entirely a product of twentieth-century chemistry. Although ergothioneine was discovered in 1909, comprehensive information on its levels in foods emerged almost a century later. The compound has no independent tradition of deliberate use in Ayurveda, Traditional Chinese Medicine, Western herbalism, or other historical medical systems, because it was not identified as a distinct entity until the twentieth century.
What can be said is that mushrooms — by far the richest dietary source of ergothioneine — do carry a long tradition of use in several cultures. However, these historical uses are attributable to the whole-mushroom context and its many bioactive constituents, and cannot be attributed specifically to ergothioneine. Ergothioneine is a sulfur-based amino acid found at its highest levels in mushrooms and fermented foods. The implicit consumption of ergothioneine through traditional mushroom-eating cultures — particularly in East Asia, Southern Europe, and elsewhere — has been invoked in ecological and epidemiological arguments (see Section 6 below), but such arguments concern dietary patterns, not deliberate use of the compound itself.
Scientific interest in ergothioneine accelerated markedly after 2005, when Dirk Gründemann and his colleagues at the University of Cologne found that humans have a powerful and highly specific transporter for the uptake of ergothioneine — sparking a scientific stir around its potential as an essential micronutrient.
3. Key Constituents, Chemical Properties, and Mechanisms of Action
3.1 Chemical Stability and Tautomerism
Ergothioneine is a histidine betaine derivative with a thiol group attached to the C2 atom of the imidazole ring. As a thione tautomer, it is a very stable antioxidant with unique properties. Unlike glutathione and ascorbate, ergothioneine can scavenge oxidizing species that are not free radicals. Ergothioneine has strong stability due to the predominance of the thione tautomer at physiological pH and circulates throughout the body in the blood plasma.
3.2 The OCTN1 Transporter (SLC22A4)
Although ergothioneine cannot be synthesized by animals, it has been shown to be widely taken up and transported into cells and tissues by the specific carnitine/organic cation transporter OCTN1 [also known as ergothioneine transporter (ETT)] on the cell membrane from food such as mushrooms, grains, and internal organs. Mammals cannot synthesize ergothioneine but possess a highly specific organic cation transporter OCTN1 (now known as solute carrier family 22 member 4, SLC22A4) allowing for efficient absorption of ergothioneine from the daily diet, leading to accumulation of ergothioneine in tissues and organs of humans and other animals.
Although OCTN-1 is a cation transporter, its transport rate of ergothioneine is 100 times higher than that of other transport substrates such as TEA and carnitine. Additionally, OCTN-1 increases the initial cellular uptake of ergothioneine — which has difficulty penetrating cell membranes — by 600 times. Owing to its hydrophilic nature, ergothioneine does not readily penetrate the cell membrane; hence, the bi-directional OCTN-1 transport regulates the accumulation and exit of ergothioneine.
Humans and animals acquire ergothioneine from the diet through the pH-dependent activity of this membrane transporter, SLC22A4, expressed on the apical membrane of the small intestine. The SLC22A4 transporter also functions in the renal reabsorption of ergothioneine in the kidney, with avid absorption and retention of ergothioneine from the diet observed in both animals and humans.
The importance of this transporter has been confirmed genetically: genetic knockout of SLC22A4 in both mice and zebrafish resulted in dramatic reduction of ergothioneine to undetectable concentrations in many tissues, and increased susceptibility to oxidative stress and inflammation, although organisms remained viable.
3.3 Antioxidant Mechanisms
Ergothioneine is capable of scavenging a diverse range of reactive oxygen and nitrogen species, has metal chelation properties, and is predicted to directly regulate nuclear factor erythroid 2-related factor 2 (Nrf2) activity. As a low molecular weight thiol, the presence of the sulfhydryl group endows it with a wide range of beneficial effects such as anti-oxidation, anti-inflammation, and detoxification, thereby preventing biomolecular damage.
In the human body, ergothioneine is transported and accumulated specifically through OCTN-1, especially in the mitochondria and nucleus, suggesting that it can target damaged cells and tissues as an antioxidant. It is considered a potent antioxidant that may participate in the antioxidant network system and promote the reducing glutathione regeneration cycle.
3.4 Anti-inflammatory Mechanisms
In vitro and in vivo evidence demonstrates that ergothioneine exerts neuroprotective effects through multiple mechanisms: scavenging reactive oxygen species, suppressing neuroinflammatory cytokines (TNF-α, IL-1β, IL-6), activating Nrf2 antioxidant pathways, and preserving mitochondrial integrity.
3.5 Longevity and Aging-Related Mechanisms
Mechanistic studies reveal that ergothioneine acts through multiple pathways: mitigating oxidative stress, reducing neuroinflammation, preserving mitochondrial function, and potentially modulating neurogenesis and NAD+ metabolism, although some mechanisms require further investigation.
Ergothioneine was found to have a positive age-prolonging effect in Drosophila melanogaster, and Caenorhabditis elegans exhibited a shorter lifespan when the ergothioneine transporter was knocked out. These findings are from pre-clinical model organisms; their relevance to human aging requires further investigation.
4. Scientific Evidence by Area of Use
4.1 Cardiovascular Disease and Mortality
Evidence strength: Observational (prospective cohort); strong epidemiological signal; causal evidence in humans lacking.
The Malmö Diet Cancer (MDC) study is a population-based prospective cohort study. During a median follow-up time of 21.4 years, 603 participants developed CVD, 362 developed diabetes mellitus, and 843 participants died. Ergothioneine was the metabolite most strongly connected to a healthy dietary pattern and was associated with a lower risk of coronary disease (HR per 1 SD increment of ergothioneine, HR=0.85, p=0.01), cardiovascular mortality (HR=0.79, p=0.002), and overall mortality (HR=0.86, p=4×10−5).
In this larger, longer-term prospective Swedish cohort (n=3,236 participants with median follow-up of 21.4 years), higher plasma levels of ergothioneine were associated with significantly lower risk of coronary disease, cardiovascular mortality, and overall mortality (hazard ratios per 1 SD increment of ergothioneine were 0.85, 0.79, and 0.86, respectively). These data reinforce preclinical studies that suggest the antioxidant and anti-inflammatory activities of ergothioneine interfere with atherogenesis and protect vascular and microvascular endothelial cells from oxidative stress and hyperglycaemia.
In a meta-analysis of prospective cohort studies (n=601,893 participants), mushroom consumption was associated with lower risk of all-cause mortality (pooled risk ratio: 0.94; 95% CI: 0.91, 0.98). It should be noted that this meta-analysis examined mushroom consumption broadly and cannot be attributed exclusively to ergothioneine content.
A critical limitation of the cardiovascular evidence is that the prospective cohort findings reflect an association between plasma ergothioneine and reduced risk; reverse causation (healthier individuals eat more mushrooms) and confounding by overall dietary quality cannot be fully excluded. Controlled interventional trials examining cardiovascular endpoints have not yet been published.
4.2 Cognitive Function, Neurodegeneration, and Brain Health
Evidence strength: Observational (moderate-strong); early-phase clinical trials (preliminary); preclinical data (strong in animal/cell models).
Low blood ergothioneine levels correlate with cognitive decline and dementia, supporting its role as a conditionally essential micronutrient for healthy aging. In a prospective elderly cohort in Singapore (n=470, mean age 73), lower baseline ergothioneine levels were associated with poorer baseline cognitive performance and faster rates of decline in function in multiple cognitive domains over 5 years of follow-up.
Individuals with mild cognitive impairment (MCI) and dementia exhibit significantly lower plasma levels of ergothioneine compared to age-matched healthy controls. An observational study revealed that lower plasma levels of ergothioneine in cognitively normal subjects correlated with faster cognitive decline and brain pathology on follow-up for up to 5 years.
Studies have shown that ergothioneine can mitigate β-amyloid toxicity in neuronal cultures, Caenorhabditis elegans, and rodent models of Alzheimer's disease. Numerous population studies have linked low blood ergothioneine levels with increased risk and progression of neurological and other age-related disorders in humans, suggesting that dietary ergothioneine may confer neuroprotective benefits. Several studies have demonstrated the efficacy of ergothioneine treatment in reducing Parkinson's disease-associated molecular damage across various pre-clinical models such as C. elegans, Drosophila, rodent models, and human neuronal cultures.
Regarding human intervention trials: whether ergothioneine supplementation (25 mg given three times a week for 52 weeks) may be beneficial in delaying or reversing cognitive decline was the subject of an ongoing clinical trial in elderly individuals with mild cognitive impairment. Observational data consistently associate low blood ergothioneine levels with cognitive impairment, neurodegenerative diseases, cardiovascular disorders, frailty, and mortality. Interventional trials in older adults suggest that ergothioneine supplementation may improve cognition, memory, sleep quality, and stabilize neurodegeneration biomarkers, with no safety concerns at doses up to 25 mg/day. These interventional findings are preliminary and based on small pilot studies; larger, independently replicated randomized controlled trials are needed.
In humans and other animals, ergothioneine is absorbed from the diet via OCTN1 encoded by the SLC22A4 gene. OCTN1 is expressed throughout the body including the brain, with several reports confirming the presence and accumulation of ergothioneine in both the mouse and human brain/cerebrospinal fluids.
4.3 Frailty and Healthy Aging
Evidence strength: Observational and metabolomic; pre-clinical; very limited clinical intervention data.
A metabolomics study of whole blood from 10 frail and nine non-frail elderly participants (mean age 84.2 ± 6.9) identified ergothioneine as a frailty marker. Low levels of ergothioneine were associated with both physical and cognitive decline. In frail elderly people, whose aging organs undergo functional decline, there is a correlation between ergothioneine levels and cognitive, but not skeletal muscle, decline.
Ergothioneine, a naturally occurring antioxidant, exhibits strong antioxidant, anti-inflammatory, and immunomodulatory activities. Age-related declines in plasma ergothioneine levels are observed, particularly in individuals with cognitive impairment. Metabolomic analyses confirm ergothioneine's beneficial effects on cognition and memory. Preclinical studies have underscored ergothioneine's potent antioxidant, anti-inflammatory, and neuroprotective effects, suggesting its potential as a therapeutic agent for cognitive frailty. However, the translation of these findings into clinical benefits necessitates validation through well-designed clinical trials.
4.4 Skin Health and Photoprotection
Evidence strength: In vitro data (moderate-strong); limited clinical human evidence.
Ergothioneine has been widely used in cosmetics, since much skin damage is caused by UV-mediated reactive oxygen species production; indeed, ergothioneine is known as a skin protectant. It shows excellent antioxidant, anti-inflammatory effects, and anti-aging properties, and inhibits melanin production.
In vitro work provides mechanistic detail: investigations of submicromolar concentrations of ergothioneine (0.125–0.5 μM) in human skin fibroblast cells showed that UVA-induced AP-1 (c-Fos and c-Jun) translocation was inhibited by ergothioneine treatments, with parallel inhibition of collagenolytic matrix metalloproteinase-1 (MMP-1) activation and type I procollagen degradation. Moreover, ergothioneine mitigated UVA-induced ROS generation. An increase in the amount of antioxidant genes (HO-1, NQO-1, and γ-GCLC) from ergothioneine was associated with upregulated Nrf2 expressions in a dose-dependent or time-dependent manner. This was confirmed from Nrf2 translocation and increased nuclear ARE promoter activity that underlie ergothioneine's dermatoprotective activities.
Regarding oral supplementation for skin outcomes in humans: a clinical investigation revealed that consecutive daily intake of ergothioneine for 28 days led to noticeable improvements in skin hydration, trans-epidermal water loss, skin elasticity, wrinkle reduction, and anti-carbonylation, all without any adverse effects. This study was open-label and of short duration; further controlled trials are needed to confirm these findings.
4.5 Diabetes and Metabolic Syndrome
Evidence strength: Preliminary; a clinical trial is in design/progress; mostly animal and observational data.
A novel food (synthetic ergothioneine) was proven to be safe under expected use conditions by the European Food Safety Authority. Supplementing the diet with ergothioneine-rich mushrooms may be beneficial to diabetics. In a dietary treatment for patients with early diabetes, eating standard white button mushroom (ergothioneine 3.2 mg/100 g) daily for 16 weeks could reduce systemic oxidative stress and inflammatory markers. This was a dietary pattern study and cannot isolate the effect of ergothioneine per se.
A clinical trial protocol — the ErgMS study — has been published, designed as a three-arm randomized, double-blind, placebo-controlled intervention trial. The ErgMS study will supplement participants with placebo, 5, or 30 mg/day ergothioneine for 12 weeks, taking measurements of metabolic syndrome risk factors, serum markers of oxidative stress (lipid peroxidation), inflammation, blood platelet function, and liver function at baseline, and after 6 weeks and 12 weeks of supplementation. Results from this trial were not yet available at the time of writing.
4.6 Sleep Quality
Evidence strength: Small randomized clinical trials; preliminary.
Randomized, double-blind clinical trials have shown that ergothioneine intake can improve sleep quality and cognitive function. No adverse effects were reported following short-term ergothioneine supplementation in small clinical trials assessing safety and sleep, with 45 and 92 participants, respectively. These trials are small and short-term; larger studies are required.
5. Body Systems and Health Areas Associated with Ergothioneine
- Central Nervous System: Ergothioneine exerts neuroprotective effects through scavenging ROS, suppressing neuroinflammatory cytokines (TNF-α, IL-1β, IL-6), activating Nrf2 antioxidant pathways, and preserving mitochondrial integrity. It is detected in brain tissue and cerebrospinal fluid via the OCTN1 transporter.
- Cardiovascular System: High plasma ergothioneine levels have been associated with significantly reduced cardiovascular mortality and overall mortality risks.
- Hematopoietic System: The ergothioneine transporter (ETT/OCTN1) occurs in a variety of tissues, with a high level of expression in the cells of the hematopoietic lineage and CD14+ cells, such as monocytes and macrophages. Erythrocytes are among the tissues with the highest ergothioneine concentrations.
- Liver and Kidney: Ergothioneine's long tissue residence time and transporter-mediated uptake enhance its potential as a diet-derived therapeutic antioxidant. Cellular and animal model studies indicate that ergothioneine concentrates in tissues susceptible to oxidative damage, such as the liver, brain, and kidneys, exerting cytoprotective effects.
- Skin and Eyes: In the human body, the largest amounts of ergothioneine are found in erythrocytes, eye lens, semen, and skin. In the skin, it provides photoprotective and anti-aging effects mediated by Nrf2 pathway activation and suppression of collagenase activity.
- Immune System: The sulfhydryl group endows ergothioneine with anti-oxidation, anti-inflammatory, and detoxification properties, thereby preventing biomolecular damage.
6. The "Longevity Vitamin" Hypothesis
L-ergothioneine has been reported to be a "longevity" vitamin because of its anti-inflammatory activities and its ability to reduce oxidative stress. Evidence from model animal and human studies increasingly suggests that ergothioneine is associated with healthy aging and activity against age-related diseases. Ergothioneine was found to have a positive age-prolonging effect in Drosophila melanogaster. They exhibit significant antioxidant properties, making them potential lead compounds for promoting health. Increasing evidence suggests that ergothioneine is positively correlated with healthy ageing and longevity.
Although a confluence of data suggests that ergothioneine acts as a powerful, pleiotropic cytoprotectant agent, and supplemental ergothioneine is already marketed direct to consumers for its anti-ageing and anti-inflammatory effects, controlled human intervention trials are just beginning to directly investigate the effects of ergothioneine supplementation in humans.
7. Dosage Forms and Reported Dosages
Ergothioneine is available as oral supplements. Manufacturer-recommended doses range from 5 to 20 mg per day. The following dosages have appeared in published clinical or regulatory contexts:
- Safety study (pharmacokinetics): One human safety study has been conducted. Forty-five healthy men of Chinese ethnicity (aged 21–35) were treated with oral placebo, 5 mg, or 25 mg L-ergothioneine daily for 7 days.
- Cognitive decline pilot trial: Ergothioneine supplementation at 25 mg given three times a week for 52 weeks was the protocol in a clinical trial in elderly individuals with mild cognitive impairment.
- ErgMS metabolic syndrome trial: The ErgMS study supplements participants with placebo, 5 or 30 mg/day ergothioneine for 12 weeks.
- EFSA-approved levels (novel food): The European Food Safety Authority reviewed a petition for the use of synthetic L-ergothioneine as a novel food ingredient at levels of up to 5 mg per serving in specific conventional foods and in dietary supplements with a recommended maximum daily dose of 30 mg L-ergothioneine per day for adults and 20 mg L-ergothioneine per day for children.
- Skin study: A clinical investigation used consecutive daily intake of ergothioneine for 28 days to assess skin health outcomes. The specific dose was not recoverable from available sources.
The L-ergothioneine derived from mushrooms has been shown to be bioavailable (taken up by red blood cells) within one hour of consumption.
8. Safety, Toxicology, and Drug Interactions
8.1 Regulatory Safety Status
Ergothioneine is approved for human consumption by the USA FDA (generally recognized as safe, GRAS status) and European Union, as well as the European Food Safety Authority. In Europe, L-ergothioneine (marketed as Ergoneine) was endorsed by the European Commission's EFSA panel in 2016, confirming its safety for use in foods and supplements. The EFSA determined that it is safe at 5 mg per serving in food and at doses of up to 30 mg/day for adults and 20 mg/day for children.
EFSA's novel food opinion states that the human studies submitted suggest there are "no relationships" between taking L-ergothioneine supplements and fortified foods and the susceptibility to or development of diabetes mellitus, Crohn's disease, or rheumatoid arthritis. EFSA's NDA panel had no concerns regarding genotoxicity at the proposed daily doses of 30 mg per day for adults and 20 mg per day for children.
8.2 Preclinical Toxicology
Rats treated with oral L-ergothioneine daily for 90 days (400, 800, 1,600 mg/kg) showed no associated mortality, changes in food consumption or body weight, or macroscopic changes at necropsy. At high doses, there was some intermittent alopecia and minor hematological changes considered non-adverse. Hematological changes were generally dose- and gender-specific. The no-observed-adverse-effect level (NOAEL) of 800 mg/kg/day (human equivalent dose = 129 mg/kg) used in safety assessments by the FDA and EFSA came from this study. No reproductive toxicity was demonstrated in a rat study (diet contained up to 0.9% L-ergothioneine). No effects were observed on mating, reproduction performance, lactation, duration of gestation, fertility, size of pups, litter size, cannibalization of pups, or litter sex ratio.
8.3 Human Clinical Safety Data
No adverse effects were reported following short-term ergothioneine supplementation in small clinical trials assessing safety and sleep, with 45 and 92 participants, respectively. Large-scale clinical trials or studies assessing the long-term effects of ergothioneine supplementation have not yet been conducted.
8.4 Known Drug Interactions
Ergothioneine may interact with some medications, including the anticonvulsants gabapentin and pregabalin. This interaction is attributed to the fact that gabapentin and pregabalin are substrates of the same large amino acid transporter system that mediates some ergothioneine transport, and thus competitive uptake may theoretically occur. This interaction has not been studied in human clinical trials.
The augmentation of low ergothioneine levels through supplementation appears to have no apparent safety concerns. A study conducted by the Panel on Dietetic Products for the European Food Safety Authority in 2017 concluded that ergothioneine is safe for children above 3 years of age and the general adult population, including pregnant and breastfeeding women.
9. Research Limitations and Evidence Gaps
The existing body of evidence for ergothioneine's health effects must be interpreted with important caveats. Most mechanistic work is in vitro or in pre-clinical animal models. Few clinical studies, which were not well-powered or well-designed, have been performed. Observational studies suggest a link between higher intake levels and healthy aging, likely by mitigating oxidative stress damage. While existing studies are promising, more large-scale clinical trials are needed to assess the potential of increasing ergothioneine intake to improve cognitive health and address brain diseases. Clinical trials conducted in diverse countries and considering different dietary patterns are imperative to ascertain whether elevating ergothioneine levels can effectively slow or prevent cognitive decline.
The observational cardiovascular data — though drawn from a large, long-duration cohort — cannot establish causality. Higher plasma ergothioneine is a marker of higher mushroom and fermented food intake, and confounding from other dietary bioactives cannot be excluded. Mushrooms containing ergothioneine are recognized for harboring a variety of other beneficial bioactive compounds aside from ergothioneine, which could also contribute to improved cognitive performance.
References
Volver